Lucence Revenue and Competitors
Estimated Revenue & Valuation
- Lucence's estimated annual revenue is currently $14.7M per year.
- Lucence's estimated revenue per employee is $155,000
Employee Data
- Lucence has 95 Employees.
- Lucence grew their employee count by -10% last year.
Lucence's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP, US Operations | Reveal Email/Phone |
2 | Clinical Laboratory Scientist III - General supervisor | Reveal Email/Phone |
3 | Medical Technologist | Reveal Email/Phone |
Lucence Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Lucence?
Lucence is an oncologist-founded precision oncology company with the vision of a world without avoidable cancer deaths. The company pioneers ultrasensitive liquid biopsy tests and state-of-the-art data analytics for early cancer detection and treatment selection. Visit www.lucence.com for more information.
keywords:N/A
N/A
Total Funding
95
Number of Employees
$14.7M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lucence News
2022-03-30 - Liquid Biopsy Market 2022 Top Leading Players, Recent Developments,
Opportunities, Size, Revenue, Sales, Regional Analysis, Business
Strategies, Challenges, Types, Applications
In November 2019, Lucence Diagnostics Pte Ltd, a genomic medicine company based in Singapore, raised US$ 20 Million in Series A funding. In June...
Other Companies in Palo Alto
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $24.1M | 95 | -16% | $80M |
#2 | $21.3M | 95 | -17% | $72M |
#3 | $25.2M | 95 | 9% | N/A |
#4 | $23.3M | 96 | -1% | N/A |
#5 | $19.6M | 96 | 8% | N/A |